platinum has been researched along with Cardiovascular Diseases in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baykan, A; Demiraldi, AG; Narin, N; Pamukcu, O; Sezer, S; Sunkak, S; Tasci, O; Uzum, K | 1 |
| Huang, NP; Simona, BR; Stauffer, F; Vörös, J; Zhang, F; Zhang, N; Zhang, ZM | 1 |
| Allocco, DJ; Calabria, P; Capodanno, D; Crowley, JJ; Dawkins, KD; Erglis, A; Gilbert, TJ; Horváth, IG; Menown, IB; Moreno, R; Tamburino, C | 1 |
| Alavijeh, OS; Cousins, BG; de Mel, A; Naghavi, N; Seifalian, AM | 1 |
1 review(s) available for platinum and Cardiovascular Diseases
| Article | Year |
|---|---|
Nitric oxide donors for cardiovascular implant applications.
Topics: Biocompatible Materials; Cardiology; Cardiovascular Diseases; Endothelium, Vascular; Gold; Humans; Hydrogels; Kinetics; Metal Nanoparticles; Nanostructures; Nanotechnology; Nitric Oxide; Nitric Oxide Donors; Platinum; Polymers; Prostheses and Implants; S-Nitrosothiols; Silicon Dioxide; Silver; Stents | 2013 |
3 other study(ies) available for platinum and Cardiovascular Diseases
| Article | Year |
|---|---|
Is hypertension the fate of aortic coarctation patients treated with Cheatham Platinum (CP) stent?
Topics: Adolescent; Aortic Coarctation; Blood Pressure Monitoring, Ambulatory; Cardiovascular Diseases; Child; Echocardiography; Female; Humans; Hypertension; Incidence; Male; Platinum; Pulse Wave Analysis; Risk Factors; Statistics as Topic; Stents; Turkey | 2018 |
Multifunctional 3D electrode platform for real-time in situ monitoring and stimulation of cardiac tissues.
Topics: Animals; Biosensing Techniques; Cardiovascular Diseases; Electric Impedance; Electric Stimulation; Electrodes; Humans; Myocardial Contraction; Myocytes, Cardiac; Platinum; Rats | 2018 |
One-year outcomes in unselected patients treated with a thin-strut, platinum-chromium, paclitaxel-eluting stent: primary endpoint results from the TAXUS Element European post-approval surveillance study (TE-PROVE).
Topics: Aged; Cardiovascular Diseases; Chromium; Coronary Restenosis; Coronary Stenosis; Drug-Eluting Stents; Europe; Female; Humans; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Paclitaxel; Percutaneous Coronary Intervention; Platinum; Product Surveillance, Postmarketing; Prospective Studies; Reoperation; Treatment Failure; Treatment Outcome; Tubulin Modulators | 2015 |